{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ertesvag NU"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["36"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9053181"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2"],"pubmed_abstract":["<h4>Background</h4>Evaluation of susceptibility to emerging SARS-CoV-2 variants of concern (VOC) requires rapid screening tests for neutralising antibodies which provide protection.<h4>Methods</h4>Firstly, we developed a receptor-binding domain-specific haemagglutination test (HAT) to Wuhan and VOC (alpha, beta, gamma and delta) and compared to pseudotype, microneutralisation and virus neutralisation assays in 835 convalescent sera. Secondly, we investigated the antibody response using the HAT after two doses of mRNA (BNT162b2) vaccination. Sera were collected at baseline, three weeks after the first and second vaccinations from older (80-99 years, <i>n</i> = 89) and younger adults (23-77 years, <i>n</i> = 310) and compared to convalescent sera from naturally infected individuals (1-89 yea"],"journal":["Communications medicine"],"pubmed_title":["A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern."],"pmcid":["PMC9053181"],"funding_grant_id":["NF-SI-0617-10139","NIHR203792","COVID-19-RECPLAS","CL-2020-13-002"],"pubmed_authors":["Oyen S","Trieu MC","Townsend A","Tondel C","Vahokoski J","Vaughan-Jackson A","Klennerman P","Jamsen A","Okkenhaug LH","Dupont M","Tan TK","Zambon M","Gopal R","Knight ML","Schimanski L","Patel M","Oxford collaborative group","Bergen COVID-19 Research Group","Skelly D","Deeks A","Onyango TB","Brokstad KA","Stafford L","Mohn KGI","Harvala H","Barnes E","Ertesvag NU","Gilbert-Jaramillo J","Kuwelker K","Amdam H","Johnson S","Cox RJ","Lartey S","James WS","Madsen A","Langeland N","Blomberg B","Zhou F","Olofsson JS","Fjelltveit E","Harding AC","Wei L","Rijal P","Linchausen DW","Ljostveit S","Bredholt G","Sandnes H","Bansal A","Akselsen PE","Roberts D","Skorge TD","Xiao J","Nguyen D","Lamikanra AA","Hansen L","Dunachie S","PHE Virology group","Sævik M"],"additional_accession":[]},"is_claimable":false,"name":"A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern.","description":"<h4>Background</h4>Evaluation of susceptibility to emerging SARS-CoV-2 variants of concern (VOC) requires rapid screening tests for neutralising antibodies which provide protection.<h4>Methods</h4>Firstly, we developed a receptor-binding domain-specific haemagglutination test (HAT) to Wuhan and VOC (alpha, beta, gamma and delta) and compared to pseudotype, microneutralisation and virus neutralisation assays in 835 convalescent sera. Secondly, we investigated the antibody response using the HAT after two doses of mRNA (BNT162b2) vaccination. Sera were collected at baseline, three weeks after the first and second vaccinations from older (80-99 years, <i>n</i> = 89) and younger adults (23-77 years, <i>n</i> = 310) and compared to convalescent sera from naturally infected individuals (1-89 yea","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-31T09:48:38.688Z","creation":"2025-04-05T15:22:16.243Z"},"accession":"S-EPMC9053181","cross_references":{"pubmed":["35603265"],"doi":["10.1038/s43856-022-00091-x"]}}